Laurie Beth Grossberg, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Inflammatory Bowel Diseases | 9 | 2022 | 2421 | 1.510 |
Why?
|
Colitis, Ulcerative | 6 | 2022 | 1919 | 1.380 |
Why?
|
Colonoscopy | 6 | 2020 | 1387 | 1.350 |
Why?
|
Crohn Disease | 6 | 2022 | 2275 | 1.110 |
Why?
|
Cytomegalovirus Infections | 2 | 2019 | 831 | 0.800 |
Why?
|
Emergency Service, Hospital | 5 | 2019 | 7818 | 0.610 |
Why?
|
Sentinel Surveillance | 1 | 2020 | 293 | 0.610 |
Why?
|
Triage | 2 | 2015 | 987 | 0.610 |
Why?
|
Guideline Adherence | 3 | 2020 | 2283 | 0.590 |
Why?
|
Practice Guidelines as Topic | 4 | 2021 | 7475 | 0.590 |
Why?
|
Intestinal Neoplasms | 1 | 2020 | 311 | 0.590 |
Why?
|
Postoperative Hemorrhage | 1 | 2019 | 422 | 0.520 |
Why?
|
Drug Monitoring | 2 | 2022 | 965 | 0.510 |
Why?
|
Gastroenterology | 1 | 2021 | 571 | 0.470 |
Why?
|
Infection Control | 1 | 2021 | 983 | 0.450 |
Why?
|
Abdominal Pain | 1 | 2019 | 1063 | 0.430 |
Why?
|
Biological Products | 1 | 2022 | 916 | 0.420 |
Why?
|
Hospital Costs | 1 | 2018 | 976 | 0.390 |
Why?
|
Early Detection of Cancer | 3 | 2020 | 3202 | 0.380 |
Why?
|
Psoriasis | 1 | 2019 | 940 | 0.370 |
Why?
|
Colorectal Neoplasms | 3 | 2019 | 6853 | 0.350 |
Why?
|
Adenoma | 2 | 2017 | 2148 | 0.350 |
Why?
|
Attitude of Health Personnel | 3 | 2020 | 3865 | 0.330 |
Why?
|
Hospitalization | 2 | 2019 | 10790 | 0.320 |
Why?
|
Interdisciplinary Communication | 1 | 2014 | 934 | 0.310 |
Why?
|
Gastrointestinal Agents | 2 | 2022 | 509 | 0.250 |
Why?
|
Tomography, X-Ray Computed | 3 | 2016 | 20509 | 0.220 |
Why?
|
Patient Care Team | 1 | 2014 | 2511 | 0.210 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2014 | 2299 | 0.190 |
Why?
|
Postoperative Complications | 2 | 2019 | 15697 | 0.170 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2022 | 778 | 0.170 |
Why?
|
Liver Neoplasms | 1 | 2014 | 4319 | 0.150 |
Why?
|
Coloring Agents | 1 | 2019 | 562 | 0.140 |
Why?
|
Cytomegalovirus | 1 | 2019 | 755 | 0.120 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2019 | 465 | 0.120 |
Why?
|
Colonic Polyps | 1 | 2019 | 551 | 0.120 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 786 | 0.120 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2020 | 867 | 0.110 |
Why?
|
Middle Aged | 12 | 2020 | 220352 | 0.110 |
Why?
|
Light | 1 | 2019 | 1344 | 0.110 |
Why?
|
Humans | 21 | 2022 | 760621 | 0.110 |
Why?
|
Logistic Models | 2 | 2019 | 13314 | 0.100 |
Why?
|
Prevalence | 3 | 2019 | 15687 | 0.100 |
Why?
|
Female | 14 | 2020 | 391270 | 0.100 |
Why?
|
Sickness Impact Profile | 1 | 2013 | 298 | 0.100 |
Why?
|
Unnecessary Procedures | 1 | 2015 | 413 | 0.100 |
Why?
|
Pimozide | 1 | 2011 | 21 | 0.100 |
Why?
|
Colonic Neoplasms | 2 | 2020 | 2526 | 0.100 |
Why?
|
Male | 13 | 2020 | 359744 | 0.090 |
Why?
|
Fellowships and Scholarships | 1 | 2019 | 1116 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2514 | 0.090 |
Why?
|
Prescription Drugs | 1 | 2017 | 630 | 0.090 |
Why?
|
STAT5 Transcription Factor | 1 | 2011 | 264 | 0.090 |
Why?
|
Iatrogenic Disease | 1 | 2013 | 538 | 0.090 |
Why?
|
Colon | 1 | 2017 | 1788 | 0.080 |
Why?
|
Hospitals, Teaching | 1 | 2014 | 1166 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2754 | 0.080 |
Why?
|
Nitrofurans | 1 | 2008 | 5 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6544 | 0.080 |
Why?
|
Societies, Medical | 1 | 2021 | 3905 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6360 | 0.080 |
Why?
|
Mortality | 1 | 2019 | 2916 | 0.080 |
Why?
|
Retrospective Studies | 4 | 2019 | 80372 | 0.070 |
Why?
|
Biopsy | 1 | 2019 | 6771 | 0.070 |
Why?
|
Irritable Bowel Syndrome | 1 | 2013 | 453 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3598 | 0.070 |
Why?
|
Patient Preference | 1 | 2014 | 922 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2017 | 4357 | 0.070 |
Why?
|
Risk Factors | 3 | 2019 | 74359 | 0.070 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12159 | 0.070 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 685 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2017 | 15289 | 0.060 |
Why?
|
Comorbidity | 1 | 2019 | 10551 | 0.060 |
Why?
|
Boston | 2 | 2016 | 9280 | 0.060 |
Why?
|
STAT3 Transcription Factor | 1 | 2008 | 877 | 0.060 |
Why?
|
Length of Stay | 1 | 2018 | 6479 | 0.060 |
Why?
|
Patient Compliance | 1 | 2014 | 2688 | 0.060 |
Why?
|
Aged, 80 and over | 2 | 2019 | 58995 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 3986 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18416 | 0.050 |
Why?
|
Aged | 4 | 2019 | 169152 | 0.050 |
Why?
|
Cell Survival | 2 | 2011 | 5797 | 0.050 |
Why?
|
Patient Selection | 1 | 2014 | 4283 | 0.050 |
Why?
|
Adult | 5 | 2020 | 219994 | 0.050 |
Why?
|
Prognosis | 1 | 2019 | 29658 | 0.040 |
Why?
|
Disease Progression | 1 | 2014 | 13502 | 0.040 |
Why?
|
Reference Standards | 1 | 2020 | 1004 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2011 | 5253 | 0.030 |
Why?
|
Young Adult | 2 | 2020 | 58741 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2020 | 718 | 0.030 |
Why?
|
Diagnosis-Related Groups | 1 | 2016 | 450 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2011 | 5643 | 0.030 |
Why?
|
Time Factors | 1 | 2014 | 40165 | 0.030 |
Why?
|
Hematocrit | 1 | 2013 | 629 | 0.020 |
Why?
|
Medical Records | 1 | 2016 | 1407 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2008 | 5130 | 0.020 |
Why?
|
United States | 1 | 2018 | 72461 | 0.020 |
Why?
|
K562 Cells | 1 | 2011 | 640 | 0.020 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2011 | 431 | 0.020 |
Why?
|
Butadienes | 1 | 2008 | 107 | 0.020 |
Why?
|
Depsipeptides | 1 | 2008 | 95 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9716 | 0.020 |
Why?
|
Janus Kinases | 1 | 2008 | 250 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2014 | 65017 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 1347 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14660 | 0.020 |
Why?
|
Risk Assessment | 2 | 2019 | 24123 | 0.020 |
Why?
|
Treatment Failure | 1 | 2011 | 2648 | 0.010 |
Why?
|
Down-Regulation | 1 | 2011 | 2913 | 0.010 |
Why?
|
Nitriles | 1 | 2008 | 956 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 10344 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6131 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1407 | 0.010 |
Why?
|
Cohort Studies | 2 | 2013 | 41335 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20080 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2803 | 0.010 |
Why?
|
Prospective Studies | 2 | 2013 | 54303 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12965 | 0.010 |
Why?
|
Phosphorylation | 1 | 2008 | 8313 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2013 | 15840 | 0.010 |
Why?
|
Models, Biological | 1 | 2011 | 9467 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2008 | 16939 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2011 | 13630 | 0.000 |
Why?
|
Adolescent | 1 | 2013 | 87810 | 0.000 |
Why?
|